---
figid: PMC6600375__ijms-20-02767-g001
figtitle: TGFB/SMAD and non-SMAD signaling
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6600375
filename: ijms-20-02767-g001.jpg
figlink: /pmc/articles/PMC6600375/figure/ijms-20-02767-f001/
number: F1
caption: TGF-β/SMAD and non-SMAD signaling. TGF-β elicits its cellular responses by
  forming ligand-induced complex formation of TGF-β type I and type II cell surface
  receptors (i.e., TβRI and TβRII) that are endowed with serine/threonine kinase activity.
  The extracellular signal is transduced across the plasma membrane through the action
  of the constitutively active TβRII kinase that phosphorylates specific serine and
  threonine residues in the intracellular juxtamembrane GS domain of TβRI. Intracellular
  signaling is then initiated when the activated TβRI kinase phosphorylates or activates
  intracellular signal mediators. In the case of the canonical SMAD pathway, TβRI
  recruits and phosphorylates specific R-SMADs, e.g., SMAD2 and SMAD3, which can form
  heteromeric complexes with SMAD4. These transcription factor complexes then translocate
  into the nucleus and cooperate with other transcription regulators to regulate target
  gene expression. In the non-SMAD pathway, TGF-β receptors activate other pathways,
  including various branches of MAPK pathways, RHO-like GTPase signaling pathways
  and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. Inhibitory signals are indicated
  with inhibitory red arrows; Stimulatory signals are indicated with green arrows.
papertitle: TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.
reftext: Yang Hao, et al. Int J Mol Sci. 2019 Jun;20(11):2767.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9563471
figid_alias: PMC6600375__F1
figtype: Figure
redirect_from: /figures/PMC6600375__F1
ndex: 1841cfd6-dee3-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6600375__ijms-20-02767-g001.html
  '@type': Dataset
  description: TGF-β/SMAD and non-SMAD signaling. TGF-β elicits its cellular responses
    by forming ligand-induced complex formation of TGF-β type I and type II cell surface
    receptors (i.e., TβRI and TβRII) that are endowed with serine/threonine kinase
    activity. The extracellular signal is transduced across the plasma membrane through
    the action of the constitutively active TβRII kinase that phosphorylates specific
    serine and threonine residues in the intracellular juxtamembrane GS domain of
    TβRI. Intracellular signaling is then initiated when the activated TβRI kinase
    phosphorylates or activates intracellular signal mediators. In the case of the
    canonical SMAD pathway, TβRI recruits and phosphorylates specific R-SMADs, e.g.,
    SMAD2 and SMAD3, which can form heteromeric complexes with SMAD4. These transcription
    factor complexes then translocate into the nucleus and cooperate with other transcription
    regulators to regulate target gene expression. In the non-SMAD pathway, TGF-β
    receptors activate other pathways, including various branches of MAPK pathways,
    RHO-like GTPase signaling pathways and phosphatidylinositol-3-kinase (PI3K)/AKT
    pathways. Inhibitory signals are indicated with inhibitory red arrows; Stimulatory
    signals are indicated with green arrows.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - dpp
  - gbb
  - put
  - mav
  - Med
  - Smox
  - Traf4
  - par-6
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Rac1
  - Rac2
  - Akt
  - Mtl
  - Cdc42
  - Dad
  - drk
  - Tak1
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Mtor
  - Tor
  - mbt
  - Pak
  - Raf
  - Mekk1
  - IKKepsilon
  - key
  - IKKbeta
  - Rho1
  - Mkk4
  - Dif
  - dl
  - Rel
  - S6k
  - Erk7
  - rl
  - bsk
  - lic
  - p38b
  - Nurf-38
  - Ebp
  - AIMP2
  - p38a
  - Hrb87F
  - p38c
  - Thor
  - tor
  - Egfr
  - TGFB1
  - TGFB2
  - TGFB3
  - TGFBR1
  - TGFBR2
  - SMAD4
  - SMAD2
  - SMAD3
  - SHC1
  - TRAF4
  - PARD6A
  - PWAR6
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - RAC1
  - RAC2
  - RAC3
  - RHOG
  - CDC42
  - SMAD7
  - GRB2
  - MAP3K7
  - NR2C2
  - SMURF1
  - SMURF2
  - XYLT2
  - SOS1
  - SOS2
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - MTOR
  - PAK2
  - PKN2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP3K1
  - MAP3K11
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - RHOA
  - MAP2K1
  - MAP2K4
  - NFKB1
  - RPS6KB1
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - MAPK14
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - EIF4EBP1
  - RORC
  - O
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
